Trial of an ayurvedic drug in prediabetes

A clinical evaluation of Agni status and trial of an ayurvedic formulation Triphala ghanvati in cases of prameha(prediabetes)

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/02/017455

Enrollment

Registered

2019-02-05

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Triphala ghanvati: Triphala ghanvati 500mg 2 bid orally with leuk warm water for 3 month with 1 month followup Control Intervention1: Metformin: Metformin 500mg 1OD orally with normal w

Eligibility

Inclusion criteria

Inclusion criteria: Plasma glucose level fasting 100-125mg/dl postprandial-140-199mg/dl HbA1c%-5.7-6.5%

Exclusion criteria

Exclusion criteria: Age 60yrs ,FBS: 125mg/dl PPBS: 199mg/dl, HbA1c: >6.5% Type2 Diabetes Mellitus(NIDDM) with & without complications Type1 Diabetes Mellitus(IDDM) with or without complications Diabetes due to endocrinopathies eg. pheochromocytoma,acromegaly,hyperthyroidism etc Drug or chemical induced diabetes mellitus eg. glucocorticoids, thyroid hormone, thiazide, phenytoin etc.

Design outcomes

Secondary

Measure	Time frame
Assesment of improvement in agni grading scaleTimepoint: 3 months duration devided into 3 followup of 1 month	—

Primary

Measure	Time frame
Assesment will be done on the basis of prepared proforma for assesment of subjective parameter this completely depends upon the symptomatology & its gradesTimepoint: 3 months duration devided into 3 followup of 1 month	—

Countries

India

Contacts

Public ContactDr Ajai kumar Pandey

Faculty of ayurveda IMS BHU

drajaipandey@gmail.com9452827885

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026